Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience

(2021) Florian Eichhorn et al.   LUNG CANCER

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

(2021) Monika Pradhan et al.   Translational Lung Cancer Research

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer

(2021) Roxana Reyes et al.   Translational Lung Cancer Research

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

(2021) Tina Cascone et al.   NATURE MEDICINE

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

(2021) J. Lee et al.   Journal of Thoracic Oncology

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

(2020) Annikka Weissferdt et al.   Clinical Lung Cancer

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY

(2020) William D. Travis et al.   Journal of Thoracic Oncology

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications

(2020) Pierre Decazes et al.   Cancers

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Learning from clinical trials of neoadjuvant checkpoint blockade

(2020) Judith M. Versluis et al.   NATURE MEDICINE

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

(2020) S.I. Rothschild et al.   ANNALS OF ONCOLOGY

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

(2020) M. Wislez et al.   ANNALS OF ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer

(2020) Wenhua Liang et al.   Translational Lung Cancer Research

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

(2019) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer

(2019) B. Sepesi et al.   Journal of Thoracic Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer

(2018) Chi-Fu Jeffrey Yang et al.   ANNALS OF THORACIC SURGERY

Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)

(2018) F. Couñago et al.   LUNG CANCER

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

(2018) Matthew J. Bott et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

(2018) Mizuki Nishino et al.   RADIOLOGY

Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement

(2018) Chao Zhang et al.   Journal of Thoracic Oncology

EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer

(2017) Ségolène Lainez et al.   RESPIRATION

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

(2015) Wilfried Ernst Erich Eberhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY